Schroder Investment Management Group Has $5.02 Million Position in Denali Therapeutics Inc. (NASDAQ:DNLI)

Schroder Investment Management Group boosted its position in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 94.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 247,800 shares of the company's stock after purchasing an additional 120,494 shares during the period. Schroder Investment Management Group owned about 0.17% of Denali Therapeutics worth $5,015,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. PNC Financial Services Group Inc. grew its holdings in Denali Therapeutics by 30.5% during the 4th quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company's stock valued at $77,000 after buying an additional 885 shares during the last quarter. KBC Group NV raised its position in shares of Denali Therapeutics by 75.8% in the 4th quarter. KBC Group NV now owns 6,334 shares of the company's stock worth $129,000 after buying an additional 2,731 shares during the period. AlphaQuest LLC raised its position in shares of Denali Therapeutics by 177.1% in the 4th quarter. AlphaQuest LLC now owns 6,961 shares of the company's stock worth $142,000 after buying an additional 4,449 shares during the period. E Fund Management Co. Ltd. raised its position in shares of Denali Therapeutics by 32.2% in the 4th quarter. E Fund Management Co. Ltd. now owns 9,997 shares of the company's stock worth $204,000 after buying an additional 2,436 shares during the period. Finally, SG Americas Securities LLC raised its position in Denali Therapeutics by 128.8% in the fourth quarter. SG Americas Securities LLC now owns 11,003 shares of the company's stock valued at $224,000 after purchasing an additional 6,195 shares during the period. 92.92% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Denali Therapeutics Price Performance

Shares of NASDAQ:DNLI traded down $0.27 on Thursday, reaching $12.59. 185,274 shares of the company traded hands, compared to its average volume of 1,231,506. Denali Therapeutics Inc. has a fifty-two week low of $10.57 and a fifty-two week high of $33.33. The company's 50 day moving average is $16.92 and its 200-day moving average is $22.06. The stock has a market capitalization of $1.83 billion, a PE ratio of -4.56 and a beta of 1.58.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.08. As a group, analysts expect that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on DNLI shares. HC Wainwright lifted their target price on Denali Therapeutics from $80.00 to $87.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. Bank of America lowered their price objective on Denali Therapeutics from $30.00 to $28.00 and set a "buy" rating for the company in a report on Monday, March 10th. William Blair reaffirmed an "outperform" rating on shares of Denali Therapeutics in a report on Friday, February 28th. Deutsche Bank Aktiengesellschaft started coverage on Denali Therapeutics in a report on Tuesday, February 11th. They set a "buy" rating and a $31.00 target price for the company. Finally, Baird R W raised Denali Therapeutics to a "strong-buy" rating in a report on Tuesday, January 7th. One analyst has rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $37.57.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.